Drug Profile
Research programme: PEDF-derived peptides - Dermadis/Hokkaido University/Kurume University
Alternative Names: DM 512Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Hokkaido University; Kurume University
- Developer Dermadis
- Class Peptides; Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psoriasis in France (Topical)